Marimastat

ArtNr	HY-12169-5mg
Hersteller	MedChem Express
CAS-Nr.	154039-60-8
Menge	5 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neuroinflammation Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer
Typ	Inhibitors
Specific against	other
Purity	99.81
Citations	[1]Rasmussen HS, et al. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75.\|[2]Yu M, et al. Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen. 2013 Jun;2(3):99-105.\|[3]van Wijngaarden J, et al. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun. 2010 Jan 8;391(2):1161-5.\|[4]Skipper JB, et al. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec. 2009;71(1):1-5.
Smiles	O=C(NO)[C@@H](O)[C@@H](CC(C)C)C(N[C@H](C(NC)=O)C(C)(C)C)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BB2516,TA2516
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	MMP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	331.41
Product Description	Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs, with potent activity against MMP-9 (IC50=3 nM), MMP-1 (IC50=5 nM), MMP-2 (IC50=6 nM), MMP-14 (IC50=9 nM) and MMP-7 (IC50=13 nM), used in the treatment of cancer. Marimastat (BB2516) is an angiogenesis and metastasis inhibitor, which limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Isoform	MMP-1; MMP-14; MMP-2; MMP-3; MMP-7
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-12169-5mg-safety-datasheet.pdf